0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessNo effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma.
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean Frédéric Blanc, André Cosme de Oliveira, Armando Santoro, Jean‐Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F. Greten, Peter R. Galle, Jean François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, M. Moscovici, D. Voliotis, Jordi Bruix (2008). Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 359(4), pp. 378-390, DOI: 10.1056/nejmoa0708857.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2008
Authors
24
Datasets
0
Total Files
0
Language
English
Journal
New England Journal of Medicine
DOI
10.1056/nejmoa0708857
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
